Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
eFFECTOR Initiates Dosing in Phase 2 Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC) | ||
By: Nasdaq / GlobeNewswire - 11 Dec 2018 | Back to overview list |
|
SAN DIEGO, Dec. 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it has dosed the first patient in a Phase 2 trial of tomivosertib (eFT508) in men with advanced castrate-resistant prostate cancer (CRPC) who experienced progression on a secondary hormonal agent. Tomivosertib is a highly selective inhibitor of MNK 1 and MNK 2 (MNK 1/2), kinases which promote tumor growth and immune evasion. “Tomivosertib is highly active in preclinical models of prostate cancer, including castrate-resistant xenografts and explant models derived directly from patients’ tumor samples,” said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. “Tomivosertib may therefore provide a new way to address treatment-resistant prostate cancers, including those which are driven by variant forms of the androgen receptor.” In completed clinical studies to date in solid tumors and lymphomas, tomivosertib was shown to be safe and well tolerated at the recommended Phase 2 dose that demonstrates clinical activity, including partial responses and prolonged stable disease in patients with advanced cancers that have failed to respond to, or relapsed after, multiple prior treatments. About Advanced Castration-resistant Prostate Cancer (CRPC) About the Phase 2 Study of Tomivosertib in Advanced CRPC In the Phase 2 study [NCT03690141], tomivosertib will be administered orally, twice a day, as monotherapy to men with CRPC. The primary endpoint of this study is anti-tumor response assessed by decline in PSA levels or objective response by iRECIST (and adaptation of RECIST used for agents with an immunomodulatory mechanism). Secondary endpoints include progression-free survival, overall survival and safety and tolerability of tomivosertib in this patient population. eFFECTOR plans to enroll approximately 30 men in the study at ten clinical sites located in United States. The company expects to report interim data from this study in the first half of 2019. About Tomivosertib (eFT508) Tomivosertib in being evaluated in multiple ongoing Phase 2 clinical studies in cancers that may respond to MNK inhibition. Patients are actively being recruited into a study of tomivosertib in castration resistant prostate cancer [NCT03690141]. Tomivosertib is also being evaluated as an add-on when patients are experiencing insufficient response to an FDA-approved checkpoint inhibitor [NCT03616834] and in combination with the PD-L1 checkpoint inhibitor avelumab in relapsed or refractory micro satellite stable colorectal cancer (MSS CRC) [NCT03258398]. As part of a clinical collaboration with Merck and Co., tomivosertib will also be tested in combination with pembrolizumab in triple negative breast cancer. Please visit www.clinicaltrials.gov for further information on ongoing clinical studies of tomivosertib. About eFFECTOR Therapeutics Contacts: Investors: Media:
|
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |